Akèy › Kansè tete negatif triple › Minnesota › Rochester
Etid klinik pou Kansè tete negatif triple nan Rochester, MN
11 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
PRE-ISPY Phase I/II Oncology Platform Program
Ap rekriteFaz 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Ap rekrite
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Mayo Clinic Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Mayo Clinic, Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic - Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Myelom Miltip24 etid
- Ensifizyans kadyak22 etid
- Kansè pwostat22 etid
- Kansè pankreyas22 etid
- Kansè Endomèt20 etid
- Kansè poumon20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.